Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06934226
Registration number
NCT06934226
Ethics application status
Date submitted
11/04/2025
Date registered
18/04/2025
Date last updated
22/06/2025
Titles & IDs
Public title
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Query!
Scientific title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Query!
Secondary ID [1]
0
0
77242113PSO3006
Query!
Secondary ID [2]
0
0
77242113PSO3006
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ICONIC-ASCEND
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Plaque Psoriasis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - JNJ-77242113
Treatment: Drugs - Matching Placebo to JNJ-77242113
Treatment: Drugs - Ustekinumab
Treatment: Drugs - Matching Placebo to Ustekinumab
Experimental: Arm 1: JNJ 77242113 - Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind.
Placebo comparator: Arm 2: Placebo - Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104.
Active comparator: Arm 3: Ustekinumab - Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.
Treatment: Drugs: JNJ-77242113
JNJ-77242113 will be administered orally.
Treatment: Drugs: Matching Placebo to JNJ-77242113
Matching placebo will be administered orally.
Treatment: Drugs: Ustekinumab
Ustekinumab will be administered subcutaneously.
Treatment: Drugs: Matching Placebo to Ustekinumab
Matching placebo will be administered subcutaneously.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Query!
Assessment method [1]
0
0
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [1]
0
0
Week 16
Query!
Primary outcome [2]
0
0
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Query!
Assessment method [2]
0
0
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [1]
0
0
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Query!
Assessment method [1]
0
0
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score.
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [2]
0
0
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Query!
Assessment method [2]
0
0
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [3]
0
0
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Query!
Assessment method [3]
0
0
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [3]
0
0
Week 16
Query!
Secondary outcome [4]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Query!
Assessment method [4]
0
0
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [4]
0
0
Week 28
Query!
Secondary outcome [5]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Query!
Assessment method [5]
0
0
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.
Query!
Timepoint [5]
0
0
Week 28
Query!
Secondary outcome [6]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Query!
Assessment method [6]
0
0
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.
Query!
Timepoint [6]
0
0
Week 28
Query!
Secondary outcome [7]
0
0
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Query!
Assessment method [7]
0
0
PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [7]
0
0
Week 16
Query!
Secondary outcome [8]
0
0
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Query!
Assessment method [8]
0
0
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [8]
0
0
Week 16
Query!
Secondary outcome [9]
0
0
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [9]
0
0
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product \& is medically important.
Query!
Timepoint [9]
0
0
Up to Week 108
Query!
Secondary outcome [10]
0
0
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Query!
Assessment method [10]
0
0
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [10]
0
0
Week 16
Query!
Secondary outcome [11]
0
0
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Query!
Assessment method [11]
0
0
DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
Query!
Timepoint [11]
0
0
Baseline up to Week 16
Query!
Secondary outcome [12]
0
0
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Query!
Assessment method [12]
0
0
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
Query!
Timepoint [12]
0
0
Week 16
Query!
Secondary outcome [13]
0
0
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Query!
Assessment method [13]
0
0
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.
Query!
Timepoint [13]
0
0
Baseline up to Week 16
Query!
Secondary outcome [14]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Query!
Assessment method [14]
0
0
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [14]
0
0
Week 28
Query!
Secondary outcome [15]
0
0
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Query!
Assessment method [15]
0
0
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [15]
0
0
Baseline up to Week 28
Query!
Secondary outcome [16]
0
0
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Query!
Assessment method [16]
0
0
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [16]
0
0
Baseline up to Week 28
Query!
Secondary outcome [17]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Query!
Assessment method [17]
0
0
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [17]
0
0
Week 28
Query!
Secondary outcome [18]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Query!
Assessment method [18]
0
0
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Query!
Timepoint [18]
0
0
Week 28
Query!
Secondary outcome [19]
0
0
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Query!
Assessment method [19]
0
0
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
Query!
Timepoint [19]
0
0
Baseline up to Week 28
Query!
Secondary outcome [20]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Query!
Assessment method [20]
0
0
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
Query!
Timepoint [20]
0
0
Week 28
Query!
Secondary outcome [21]
0
0
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Query!
Assessment method [21]
0
0
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.
Query!
Timepoint [21]
0
0
Baseline up to Week 16
Query!
Secondary outcome [22]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Query!
Assessment method [22]
0
0
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Query!
Timepoint [22]
0
0
Week 16
Query!
Secondary outcome [23]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Query!
Assessment method [23]
0
0
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.
Query!
Timepoint [23]
0
0
Week 16
Query!
Secondary outcome [24]
0
0
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Query!
Assessment method [24]
0
0
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.
Query!
Timepoint [24]
0
0
Week 16
Query!
Eligibility
Key inclusion criteria
* Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
* Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
* Total psoriasis area and severity index (PASI) >=12 at screening and baseline
* Total investigator global assessment (IGA) >=3 at screening and baseline
* Candidate for phototherapy or systemic treatment for plaque psoriasis
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
* Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
* Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
* Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/04/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
29/12/2027
Query!
Actual
Query!
Sample size
Target
675
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [2]
0
0
Cornerstone Dermatology - Coorparoo
Query!
Recruitment hospital [3]
0
0
Premier Specialists - Kogarah
Query!
Recruitment hospital [4]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment hospital [5]
0
0
Royal Melbourne Hospital - Melbourne
Query!
Recruitment hospital [6]
0
0
ISHI dermatology - Mitcham
Query!
Recruitment hospital [7]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [8]
0
0
Veracity Clinical Research - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [2]
0
0
4151 - Coorparoo
Query!
Recruitment postcode(s) [3]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [5]
0
0
3050 - Melbourne
Query!
Recruitment postcode(s) [6]
0
0
3132 - Mitcham
Query!
Recruitment postcode(s) [7]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [8]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Iowa
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Oregon
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Pennsylvania
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
South Dakota
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Utah
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Washington
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Barrio Gral Paz Cba Capital
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Buenos Aires
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Caba
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Rosario
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
San Fernando
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Tucuman
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Feldkirch
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Linz
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Sankt Polten
Query!
Country [33]
0
0
Austria
Query!
State/province [33]
0
0
Wien
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Brussel
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Gent
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Ghent
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Leuven
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Liege
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Maldegem
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Newfoundland and Labrador
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Ontario
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Quebec
Query!
Country [43]
0
0
Denmark
Query!
State/province [43]
0
0
Aalborg
Query!
Country [44]
0
0
Denmark
Query!
State/province [44]
0
0
Aarhus
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Hellerup
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Kobenhavn NV
Query!
Country [47]
0
0
Denmark
Query!
State/province [47]
0
0
Odense
Query!
Country [48]
0
0
Denmark
Query!
State/province [48]
0
0
Roskilde
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Augsburg
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Bad Bentheim
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Berlin
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Bonn
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Bramsche
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Darmstadt
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Dresden
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Friedrichshafen
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Kiel
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Langenau
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Mahlow
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Mainz
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Muenster
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Witten
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Budapest
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Debrecen
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Gyongyos
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Gyula
Query!
Country [67]
0
0
Hungary
Query!
State/province [67]
0
0
Hodmezovasarhely
Query!
Country [68]
0
0
Hungary
Query!
State/province [68]
0
0
Kaposvar
Query!
Country [69]
0
0
Hungary
Query!
State/province [69]
0
0
Kecskemet
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Szolnok
Query!
Country [71]
0
0
Hungary
Query!
State/province [71]
0
0
Veszprem
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Bialystok
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Elblag
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Katowice
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Krakow
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Lodz
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Olsztyn
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Poznan
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Skierniewice
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Warszawa
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Wroclaw
Query!
Country [82]
0
0
Portugal
Query!
State/province [82]
0
0
Braga
Query!
Country [83]
0
0
Portugal
Query!
State/province [83]
0
0
Leiria
Query!
Country [84]
0
0
Portugal
Query!
State/province [84]
0
0
Lisboa
Query!
Country [85]
0
0
Portugal
Query!
State/province [85]
0
0
Porto
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Alicante
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Barakaldo
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Barcelona
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Granada
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Madrid
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Manises
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Santiago Compostela
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Sevilla
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Valencia
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Villajoyosa
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Zaragoza
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Dudley
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Harrow
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Kings Lynn
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
London
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Reading
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Salford
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Southampton
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Wakefield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06934226
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Study Contact
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
844-434-4210
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06934226
Download to PDF